(Q33402553)

English

A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer (English)

1 reference

Europe PubMed Central

26 July 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Laura J. Havrilesky

6

object named as

Laura J Havrilesky

1 reference

Europe PubMed Central

26 July 2017

Angeles Alvarez Secord

1

object named as

Angeles Alvarez Secord

1 reference

Europe PubMed Central

26 July 2017

Gloria Broadwater

5

object named as

Gloria Broadwater

1 reference

Europe PubMed Central

26 July 2017

Andrew Berchuck

8

object named as

Andrew Berchuck

1 reference

Europe PubMed Central

26 July 2017

2

object named as

Deanna K Teoh

1 reference

Europe PubMed Central

26 July 2017

Robert M Wenham

10

object named as

Robert M Wenham

1 reference

Europe PubMed Central

26 July 2017

author name string

William T Barry

3

1 reference

Europe PubMed Central

26 July 2017

Miao Yu

4

1 reference

Europe PubMed Central

26 July 2017

Paula S Lee

7

1 reference

Europe PubMed Central

26 July 2017

Johnathan Lancaster

9

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

26 July 2012

1 reference

Europe PubMed Central

26 July 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

26 July 2017

18

1 reference

Europe PubMed Central

26 July 2017

19

1 reference

Europe PubMed Central

26 July 2017

5489-5498

1 reference

Europe PubMed Central

26 July 2017

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Src is a major signaling component for CTGF induction by TGF-beta1 in osteoblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

A pathway-based classification of human breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

GenePattern 2.0

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Significance analysis of functional categories in gene expression studies: a structured permutation approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Summaries of Affymetrix GeneChip probe level data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

14 July 2018

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

31 October 2018

Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

31 October 2018

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3463759

31 October 2018

Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8

1 reference

https://pubmed.ncbi.nlm.nih.gov/22837181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-12-0507

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33402553&oldid=1749477975"